{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T08:55:23Z","timestamp":1768899323936,"version":"3.49.0"},"reference-count":12,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T00:00:00Z","timestamp":1702080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Addict"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>In April 2021, the Department of Health and Human Services released new federal practice guidelines and allowed physicians who wish to treat \u226430 patients with opioid use disorder (OUD) to forego the X\u2010waiver training requirement.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This observational study compared annual number, dose, and spending of buprenorphine OUD treatments dispensed in the Medicaid population in 2021 versus 2020 using the CMS State Drug Utilization Data (<jats:italic>n<\/jats:italic>\u2009=\u200950 states plus D.C.).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared to 2020, there was a slight decrease (\u22123.1%) in the annual number of buprenorphine prescriptions dispensed but an increase in total doses (+3.2%) and payment (10.6%) for buprenorphine prescriptions in 2021.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion and Conclusions<\/jats:title><jats:p>Decrease in number of buprenorphine prescriptions in Medicaid population was observed in 2021.<\/jats:p><\/jats:sec><jats:sec><jats:title>Scientific Significance<\/jats:title><jats:p>Our findings support the hypothesis generation in which the removal of X\u2010waiver training alone is not adequate to increase prescribing and access to OUD treatment buprenorphine.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajad.13505","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T09:53:45Z","timestamp":1702115625000},"page":"335-338","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Did the 2021 federal change in the practice guidelines for the administration of buprenorphine for treating opioid use disorder increase buprenorphine prescription dispensing in Medicaid population?"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4624-9963","authenticated-orcid":false,"given":"Jingjing","family":"Qian","sequence":"first","affiliation":[{"name":"Department of Health Outcomes Research and Policy Auburn University Harrison College of Pharmacy Auburn Alabama USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6532-2439","authenticated-orcid":false,"given":"Asmita P.","family":"Khatiwada","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes Research and Policy Auburn University Harrison College of Pharmacy Auburn Alabama USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangzhong","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes Research and Policy Auburn University Harrison College of Pharmacy Auburn Alabama USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,12,9]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"Centers for Disease Control and Prevention (CDC).Death rate maps & graphs: drug overdose deaths remain high;2022. Accessed June 24 2022.https:\/\/www.cdc.gov\/drugoverdose\/deaths\/index.html"},{"key":"e_1_2_6_3_1","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA).Buprenorphine;2022. Accessed June 24 2022.https:\/\/www.samhsa.gov\/medication-assisted-treatment\/medications-counseling-related-conditions\/buprenorphine"},{"key":"e_1_2_6_4_1","unstructured":"Congress.gov.H.R.2634\u2014drug addiction treatment act of 2000;2000. Accessed June 24 2022.https:\/\/www.congress.gov\/bill\/106th-congress\/house-bill\/2634"},{"key":"e_1_2_6_5_1","unstructured":"Federal Register.Practice guidelines for the administration of buprenorphine for treating opioid use disorder;2021. Accessed June 24 2022.https:\/\/www.federalregister.gov\/documents\/2021\/04\/28\/2021-08961\/practice-guidelines-for-the-administration-of-buprenorphine-for-treating-opioid-use-disorder"},{"key":"e_1_2_6_6_1","unstructured":"U.S. Department of Justice.Drug Enforcement Administration;2023. Accessed January 25 2023.https:\/\/www.deadiversion.usdoj.gov\/pubs\/docs\/A-23-0020-Dear-Registrant-Letter-Signed.pdf"},{"key":"e_1_2_6_7_1","unstructured":"Medicaid.gov.State drug utilization data;2022. Accessed June 24 2022.https:\/\/www.medicaid.gov\/medicaid\/prescription-drugs\/state-drug-utilization-data\/index.html"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2023.100135"},{"key":"e_1_2_6_9_1","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA).Results from the 2019 National Survey on Drug Use and Health: detailed tables;2022. Accessed on June 25 2022.https:\/\/www.samhsa.gov\/data\/report\/2019-nsduh-detailed-tables"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2021.1903659"},{"key":"e_1_2_6_11_1","unstructured":"Centers for Medicare & Medicaid Services.Medicaid opioid prescribing rates by geography. Accessed on October 25 \u00a02023.\u00a0https:\/\/data.cms.gov\/summary-statistics-on-use-and-payments\/medicare-medicaid-opioid-prescribing-rates\/medicaid-opioid-prescribing-rates-by-geography"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-06255-6"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.3549"}],"container-title":["The American Journal on Addictions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajad.13505","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T11:32:52Z","timestamp":1713612772000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajad.13505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,9]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/ajad.13505"],"URL":"https:\/\/doi.org\/10.1111\/ajad.13505","archive":["Portico"],"relation":{},"ISSN":["1055-0496","1521-0391"],"issn-type":[{"value":"1055-0496","type":"print"},{"value":"1521-0391","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,9]]},"assertion":[{"value":"2023-08-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}